A phase i study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer

Human Gene Therapy

Volumn 22, Issue 3, 2011, Pages 336-342

  Tarhini, Ahmad A ^a   Belani, Chandra P ^b   Luketich, James D ^a   Argiris, Athanassios ^a   Ramalingam, Suresh S ^c   Gooding, William ^a   Pennathur, Arjun ^a   Petro, Daniel ^a   Kane, Kevin ^a   Liggitt, Denny ^d   Championsmith, Tony ^e   Zhang, Xichen ^a   Epperly, Michael W ^a   Greenberger, Joel S ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e PharmaReg Consultants   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; MANGANESE SUPEROXIDE DISMUTASE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALLERGY; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DEHYDRATION; DERMATITIS; DISEASE SEVERITY; DNA EXTRACTION; DRUG DOSE ESCALATION; DRUG ERUPTION; DYSPEPSIA; DYSPHAGIA; DYSPNEA; ESOPHAGITIS; ESOPHAGOSCOPY; ESOPHAGUS STRICTURE; FATIGUE; FEMALE; HEADACHE; HEART ATRIUM FIBRILLATION; HEMOPTYSIS; HEMORRHOID HEMORRHAGE; HIP PAIN; HISTOPATHOLOGY; HOARSENESS; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INSOMNIA; LIMB PAIN; LIPOSOMAL DELIVERY; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PLASMID; PNEUMONIA; POLYMERASE CHAIN REACTION; RADIATION DOSE DISTRIBUTION; RESTLESSNESS; SENSORY NEUROPATHY; SIDE EFFECT; SOMNOLENCE; SQUAMOUS CELL; SUPRAVENTRICULAR TACHYCARDIA; THORACIC RADIOTHERAPY; THROMBOCYTOPENIA; THROMBOEMBOLISM; THRUSH; TRANSGENE; TREATMENT RESPONSE; TUMOR BIOPSY; VOMITING; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; ESOPHAGUS; FEMALE; GENE THERAPY; HUMANS; LIPOSOMES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PLASMIDS; POLYMERASE CHAIN REACTION; SUPEROXIDE DISMUTASE; TRANSGENES; TREATMENT OUTCOME;

EID: 79952686010     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2010.078     Document Type: Article

References (43)

1. Bahri, S., Flickinger, J.C., Kalend, A.M., et al. (1999). Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams. Radiat. Oncol. Investig. 7, 297-308. (Pubitemid 29522078)
2. Belani, C.P., Aisner, J., and Day, R. (1997). Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC); three year followup. Proc. Am. Soc. Clin. Oncol. 16, 448a (Abstr.
3. Byhardt, R.W., Martin, L., Pajak, T.F., et al. (1993). The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC)-analysis of a Radiation Therapy Oncology Group (RTOG) protocol. Int. J. Radiat. Oncol. Biol. Phys. 27, 537-544. (Pubitemid 23331119)
4. Byhardt, R.W., Scott, C., Sause, W.T., et al. (1998). Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int. J. Radiat. Oncol. Biol. Phys. 42, 469-478. (Pubitemid 28501093)
5. Choi, N.C., Herndon, J.E. 2nd, Rosenman, J., et al. (1998). Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J. Clin. Oncol. 16, 3528-3536. (Pubitemid 28506764)
6. Choy, H., and Browne, M.J. (1995). Paclitaxel as a radiation sensitizer in non-small cell lung cancer. Semin. Oncol. 22(3 Suppl 6), 70-74.
7. Choy, H., Akerley, W., Safran, H., et al. (1996). Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer. Semin. Oncol. 23(6 Suppl 16), 117-119. (Pubitemid 27069002)
8. Choy, H., DeVore, R.F. 3rd, Hande, K.R., et al. (1997). Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer. Semin. Oncol. 24(4 Suppl 12), S12-21-S12-26. (Pubitemid 27435195)
9. Choy, H., DeVore, R.F. 3rd, and Hande, K.R. (1998a). Phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer: a Vanderbilt Cancer Center Affiliate Network (VCCAN) trial. Proc. Am. Soc. Clin. Oncol. 17, 467a (Abstr. 1794
10. Choy, H., Akerley, W., Safran, H., et al. (1998b). Multi-institutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J. Clin. Oncol. 16, 3316-3322. (Pubitemid 28481627)
11. Choy, H., Akerley, W., and DeVore, R.F. 3rd. (1999). Concurrent paclitaxel, carboplatin, and radiation therapy for locally advanced non-small cell lung cancer. Semin. Oncol. 26(1 Suppl 2), 36-43. (Pubitemid 29153683)
12. Curran, W.J., Scott, C., and Langer, C.J. (2002). Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc. Am. Soc. Clin. Oncol. 19, 484a.
13. Curran, W.J., Scott, C.B., and Langer, C.J. (2003). Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected state III nsclc: RTOG 9410. Proc. Am. Soc. Clin. Oncol. 22, 621 (Abstr. 2499
14. Dillman, R.O., Seagren, S.L., Propert, K.J., et al. (1990). A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N. Engl. J. Med. 323, 940-945. (Pubitemid 20332333)
15. Epperly, M.W., Bray, J.A., Escobar, P., et al. (1998a). Over-expression of the human MnSOD transgene in vitro protects 32D cl 3 murine hematopoietic progenitor cells from irradiation-induced apoptosis. ASTRO 40th Annual Scientific Meeting, Phoenix, AZ, October 25-29, 1998. Int. J. Radiat. Oncol. Biol. Phys. 42(Suppl), 125 (#23
16. Epperly, M., Bray, J., Kraeger, S., et al. (1998b). Prevention of late effects of irradiation lung damage by manganese superoxide dismutase gene therapy. Gene Ther. 5, 196-208. (Pubitemid 28077747)
17. Epperly, M.W., Bray, J.A., Krager, S., et al. (1999). Intratracheal injection of adenovirus containing the human MnSOD trans-gene protects athymic nude mice from irradiation-induced organizing alveolitis. Int. J. Radiat. Oncol. Biol. Phys. 43, 169-181. (Pubitemid 29065842)
18. Epperly, M.W., Sikora, C., DeFilippi, S., et al. (2000). Plasmid/ liposome transfer of the human manganese superoxide dis-mutase transgene prevents ionizing irradiation-induced apo-ptosis in human esophagus organ explant culture. Int. J. Cancer 90, 128-137. (Pubitemid 30441513)
19. Epperly, M.W., Gretton, J.A., DeFilippi, S.J., et al. (2001). Modulation of radiation-induced cytokine elevation associated with esophagitis and esophageal stricture by manganese su-peroxide dismutase-plasmid/liposome (SOD2-PL) gene therapy. Radiat. Res. 155(1 Pt 1), 2-14. (Pubitemid 32125734)
20. Furuse, K., Fukuoka, M., Kawahara, M., et al. (1999). Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in un-resectable stage III non-small-cell lung cancer. J. Clin. Oncol. 17, 2692-2699. (Pubitemid 29415225)
21. Gandara, D.R., Chansky, K., Albain, K.S., et al. (2003). Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J. Clin. Oncol. 21, 2004-2010. (Pubitemid 46606390)
22. Grdina, D.J., Carnes, B.A., Grahn, D., and Sigdestad, C.P. (1991). Protection against late effects of radiation by S-2-(3-aminopro-pylamino)- ethylphosphorothioic acid. Cancer Res. 51, 4125-4130.
23. Greenberger, J.S., Kalend, A., Sciurba, F., et al. (1996). Development of multifield three-dimensional conformal radiotherapy of lung cancer using a total lung dose/volume histogram. Radiat. Oncol. Investig. Clin. Basic Res. 3, 243-255.
24. Heckl, K. (1988). Isolation of cDNAs encoding human manganese superoxide dismutase. Nucleic Acids Res. 16, 6224.
25. Ishii, K.J., and Akira, S. (2006). Innate immune recognition of, and regulation by, DNA. Trends Immunol. 27, 525-532. (Pubitemid 44515161)
26. Jeremic, B., Jevremovic, S., Mijatovic, L., and Milisavljevic, S. (1993). Hyperfractionated radiation therapy with and without concurrent chemotherapy for advanced non-small cell lung cancer. Cancer 71, 3732-3736. (Pubitemid 23152691)
27. Langer, C., Hudes, R., and Movsas, B. (1997a). Induction pacli-taxel and carboplatin followed bv concurrent chemor-adiotherapy in unresectable, locally advanced non-small cell lung cancer: report of FCCC 94-001. Lung Cancer 18, 74 (S1)
28. Langer, C.J., Movsas, B., Hudes, R., et al. (1997b). Induction paclitaxel and carboplatin followed by concurrent chemor-adiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center Study 94-001. Semin. Oncol. 24(4 Suppl 12), S12-89-S12-95. (Pubitemid 27435209)
29. Lau, D.H.M., Ryu, J.K., Gandara, D.R., et al. (1997). Twice-weekly paclitaxel and radiation for stage III non-small cell lung cancer. Semin. Oncol. 24(4 Suppl 12), S12-106-S12-109. (Pubitemid 27435212)
30. Lau, D., Leigh, B., and Gandara, D. (1999). Weekly carboplatin, twice-weekly paclitaxel, and thoracic radiation followed by carboplatin/ paclitaxel for stage III non-small cell lung cancer. Semin. Oncol. 26(Suppl 2), 70 (Abstr.
31. Le Chevalier, T., Arriagada, R., Quoix, E., et al. (1991). Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J. Natl. Cancer Inst. 83, 417-423.
32. Maguire, P.D., Sibley, M.D., and Zhou, S.M. (1998). Length of circumferential esophagus within the high dose radiotherapy field predicts for late esophageal dysfunction. Int. J. Rad. Oncol. Biol. Phys. 92(Suppl 1), 200 (151A
33. Mattson, K. (1998). Paclitaxel and carboplatin followed by concomitant paclitaxel/cisplatin/radiation therapy in inoperable non-small cell lung cancer. The Fox Chase Cancer Center and Free University Hospital Paclitaxel Investigators' Workshop and Consensus Conference. St.Thomas, U.S. Virgin Islands, March 26-28, 1998: Oral Presentation.
34. Nagler, R.M., and Laufer, D. (1998). Protection against irradiation-induced damage to salivary glands by adrenergic agonist administration. Int. J. Radiat. Oncol. Biol. Phys. 40, 477-481. (Pubitemid 28114397)
35. Newton, G.L., Aguilera, J.A., Kim, T., et al. (1996). Transport of aminothiol radioprotectors into mammalian cells: passive diffusion versus mediated uptake. Radiat. Res. 146, 206-215. (Pubitemid 26260370)
36. Oetzel, D., Schraube, P., Hensley, F., et al. (1995). Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. Int. J. Radiat. Oncol. Biol. Phys. 33, 455-460.
37. Perez, C.A., Stanley, K., Rubin, P., et al. (1980). A prospective randomized study of various irradiation doses and fraction-ation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer 45, 2744-2753. (Pubitemid 10063330)
38. Sause, W.T., Scott, C., Taylor, S., et al. (1995). Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J. Natl. Cancer. Inst. 87, 198-205.
39. Socinski, M.A., Clark, J.A., Halle, J., et al. (1997). Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial. Semin. Oncol. 24(4 Suppl 12), S12-117-S12-122. (Pubitemid 27435215)
40. Socinski, M.A., Clark, J., and Halle, J. (1998). Induction carboplatin/paclitaxel (CP) followed by concurrent CP and dose-escalating thoracic conformal radiation therapy (TCRT) in stage III non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 17, 500a (Abstr. 1928
41. Stenglein, M.D., Burns, M.B., Li, M., et al. (2010). APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat. Struct. Mol. Biol. 17, 222-229.
42. Wheldon, T.E., Mairs, R.J., Rampling, R.P., and Barrett, A. (1998). Modelling the enhancement of fractionated radiotherapy by gene transfer to sensitize tumour cells to radiation. Radiother. Oncol. 48, 5-13. (Pubitemid 28391962)
43. Wong, G.H., Elwell, J.H., Oberley, L.W., and Goeddel, D.V. (1989). Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 58, 923-931. (Pubitemid 19227900)